Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- AUTL
- Price
- 2.05
- Stock movement up
- +0.02 (1.16%)
- Company name
- Autolus Therapeutics Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 465.75M
- Ent value
- 159.20M
- Price/Sales
- 39.25
- Price/Book
- 0.98
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -54.43%
- 3 year return
- -21.73%
- 5 year return
- -35.76%
- 10 year return
- -
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
AUTL does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 39.25 |
| Price to Book | 0.98 |
| EV to Sales | 13.42 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 266.14M |
| EPS (TTM) | -1.02 |
| FCF per share (TTM) | -0.77 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 11.87M |
| Gross profit (TTM) | 6.17M |
| Operating income (TTM) | -206.45M |
| Net income (TTM) | -270.23M |
| EPS (TTM) | -1.02 |
| EPS (1y forward) | -0.73 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 51.97% |
| Operating margin (TTM) | -1739.83% |
| Profit margin (TTM) | -2277.32% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 657.07M |
| Net receivables | 993.00K |
| Total current assets | 718.11M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 140.02M |
| Total assets | 827.49M |
| Accounts payable | 1.42M |
| Short/Current long term debt | 52.23M |
| Total current liabilities | 52.47M |
| Total liabilities | 350.52M |
| Shareholder's equity | 476.96M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -193.17M |
| Capital expenditures (TTM) | 12.44M |
| Free cash flow (TTM) | -205.61M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -56.66% |
| Return on Assets | -32.66% |
| Return on Invested Capital | -56.23% |
| Cash Return on Invested Capital | -42.79% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.71 |
| Daily high | 1.78 |
| Daily low | 1.71 |
| Daily Volume | 2.26M |
| All-time high | 48.01 |
| 1y analyst estimate | 9.62 |
| Beta | 1.90 |
| EPS (TTM) | -1.02 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 30 Oct 2025 |
Downside potential
Loading...
Downside potential data
| AUTL | S&P500 | |
| Current price drop from All-time high | -96.35% | -1.46% |
| Highest price drop | -97.63% | -56.47% |
| Date of highest drop | 10 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -79.51% | -10.99% |
| Avg time to new high | 164 days | 12 days |
| Max time to new high | 1703 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
465.75M
Marketcap category
Small-cap
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Employees
647
Website
Investor relations
-
SEC filings
CEO
Christian Martin Itin
Country
USA
City
London
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page